News

COPD Hospital Readmission Rates Linked to Readmission for Other Diseases and Patient Care

Hospital readmissions for chronic obstructive pulmonary disease (COPD) are linked to readmissions for other conditions as well as patients’ own experiences while hospitalized, such as communication with nurses, staff responsiveness, pain management and discharge information. The study reporting the findings is titled “Chronic Obstructive Pulmonary Disease Readmissions and…

Pulmatrix Issued European Patent for iSPERSE Inhaled Drug Technology

Pulmatrix was granted an important patent from the European Union (EU) for its proprietary iSPERSE technology, a platform for inhaled drug delivery based on unique properties developed for the treatment of lung diseases such as chronic obstructive pulmonary disease (COPD). “This new patent shows our continued ability to obtain patents that protect…

AstraZeneca and Circassia Partnering on COPD Inhalants

AstraZeneca and Circassia are partnering to develop and commercialize two inhaled respiratory treatments for chronic obstructive pulmonary disease (COPD) in the United States, Tudorza (aclidinium bromide) and Duaklir (aclidinium bromide). Tudorza was approved by the U.S. Food and Drug Administration (FDA) in 2012, and its marketing began that…

Bronchiectasis in COPD Linked to Sinus Inflammation

Chronic inflammation of the sinus cavities is more common among patients with chronic obstructive pulmonary disease (COPD) who also have bronchiectasis, underscoring the impact of chronic inflammation of the upper airways in more severe disease phases. The study, “Chronic rhinosinusitis is associated with higher prevalence and severity…